Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Slides:



Advertisements
Similar presentations
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Advertisements

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Diffuse Large Cell Lymphoma Cell of Origin – Ready for Prime Time? Thomas Witzig, MD Hematology.
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
Spotlight on Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma: European and US Perspectives on the Evolving Standard of Care Bruce Cheson,
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood &
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Follicular & Aggressive B-Cell Lymphomas. Five-year TTF and Response Duration (RD) According to FLIPI Risk Group R-CHOPCHOPP value TTF Low-risk
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
Radioimmunotherapy as Consolidation in MCL (Mantle Cell Lymphoma) — 8 Years Follow-Up of a Prospective Phase 2 Polish Lymphoma Research Group Study Jurczak.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
1 Nowakowski GS et al. Proc ASH 2012;Abstract 689.
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
Ruan J et al. Proc ASH 2013;Abstract 247.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Bachy and Salles. Seminars in Hematology, Vol 52, No 2, April 2015.
1 Flinn I et al. Proc ICML 2013;Abstract 084.
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and at the End of Treatment with R-CHOP in High- Tumor Mass Follicular.
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
Prognostic value of PET-CT after frontline therapy in follicular lymphoma: a pooled analysis of central review in three multicenter studies. J Trotman,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
CCO Independent Conference Highlights
CCO Independent Conference Highlights
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Reeder CB et al. ASCO 2009; Abstract (Poster)
REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction New Findings in Hematology: Independent Conference.
Fujiwara H et al. Proc ASH 2015;Abstract 181.
Innovations and Issues in Mantle Cell Lymphoma
Advances in Lymphoma.
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
Jonathan W. Friedberg M.D., M.M.Sc.
Updates in Lymphoma From Recent Congresses
Jonathan W. Friedberg M.D., M.M.Sc.
Recent Advances in the Treatment of Lymphoma
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.
Presented By Andrew Evens at 2016 ASCO Annual Meeting
Presentation transcript:

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting

Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP? Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 4 Presented By Sonali Smith at 2014 ASCO Annual Meeting

Rituximab clearance by age and gender and study design Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 6 Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 7 Presented By Sonali Smith at 2014 ASCO Annual Meeting

Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP? Presented By Sonali Smith at 2014 ASCO Annual Meeting

Synthetic lethality of lenalidomide in ABC-DLBCL and clinical proof of principle Presented By Sonali Smith at 2014 ASCO Annual Meeting

PFS by GCB vs. non-GCB Subtype* in RCHOP Case-matched Control and R2CHOP Patients Presented By Sonali Smith at 2014 ASCO Annual Meeting

OS by GCB vs. non-GCB Subtype in RCHOP Case-matched Control and R2CHOP Patients Presented By Sonali Smith at 2014 ASCO Annual Meeting

PFS by Treatment Type in GCB vs. non-GCB Subtype Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting

FL survival is improving for most patients Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstract 8502: 246 patients with reviewed postinduction PET-CT Presented By Sonali Smith at 2014 ASCO Annual Meeting

CT & BM based response (IWC 1999 criteria) Presented By Sonali Smith at 2014 ASCO Annual Meeting

Both PET cut-offs predictive of PFS Presented By Sonali Smith at 2014 ASCO Annual Meeting

Postinduction PET status (cut-off ≥4) and Overall Survival Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting

Mantle Cell Lymphoma 2014 Presented By Sonali Smith at 2014 ASCO Annual Meeting

CHOP ± Rituximab in MCL: Progression-Free Survival Presented By Sonali Smith at 2014 ASCO Annual Meeting

Approved agents for R/R MCL (Variable intensity of prior Rx among studies) Presented By Sonali Smith at 2014 ASCO Annual Meeting

LYM-3002: Replace vincristine with bortezomib Presented By Sonali Smith at 2014 ASCO Annual Meeting

Superior PFS by IRC with VR-CAP vs R-CHOP: 59% improvement Presented By Sonali Smith at 2014 ASCO Annual Meeting

Peripheral Neuropathy Presented By Sonali Smith at 2014 ASCO Annual Meeting

Conclusions – Efficacy Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting

Take-home points Presented By Sonali Smith at 2014 ASCO Annual Meeting